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Background 
Heart failure (HF) is a major public health 
problem and is more common in the black 
population.  It affects approximately 3% of all 
adult black Americans.  Black patients develop 
HF symptoms at an earlier age than non-black 
patients.  This may be due to the fact that black 
patients are more likely to have hypertension and 
diabetes than non-black patients.  They more 
frequently exhibit sodium retention, ventricular 
hypertrophy, and vascular injury.  When 
diagnosed, HF progresses more rapidly in black 
than in white patients, as evidenced by a higher 
risk of initial and recurrent hospitalization and 
death.1   
In the U. S. the prevalence of high blood 
pressure (HBP) in African Americans is among 
the highest in the world.  They develop HBP 
earlier in life and have higher average blood 
pressures.  Blacks have a 1.3 times greater rate of 
nonfatal stroke, a 1.8 times greater rate of fatal 
stroke, a 1.5 times greater rate of heart disease 
death, and a 4.2 times greater rate of end-stage 
renal disease than whites.2   
Because racial minorities with HF are under-
represented in HF clinical trials of new drugs, 
little is known about their response to medications 
used in the management of HF.  
Recommendations for management of HF call for 
control of systolic and diastolic hypertension.1 
Most African Americans require combination 
antihypertensive therapy to reach appropriate 
blood pressure levels.  The Hypertension in 
African Americans Working (HAAW) Group’s 
consensus statement suggests the combination of 
agents to achieve target blood pressure when 
required.  Combinations include beta-
blocker/diuretic, angiotensin-converting enzyme 
inhibitor (ACEI)/diuretic, ACEI/calcium-channel 
blocker (CCB), or angiotensin-receptor blocker 
(ARB)/diuretic dual therapies.3 
The African-American Heart Failure Trial (A-
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This study was a randomized, placebo-
controlled, double-blind trial of 1,050 black 
patients at least 18 years of age or older.  These 
self-identified African Americans had New York 
Heart Association class III or IV heart failure with 
dilated ventricles.  All had a baseline mean 
ejection fraction of 24% and were already 
receiving standard therapy for heart failure.  
Patients were randomly assigned to receive fixed 
doses of isosorbide dinitrate (20 to 40 mg) plus 
hydralazine (37.5 to 75 mg) orally three times 
daily or placebo three times daily.  In addition all 
participants continued their standard heart failure 
therapy.  Standard therapy included diuretics, 
ACEIs, ARBs, beta-blockers, carvedilol, digoxin, 
or spironolactone.  Stratification into groups was 
based on use or nonuse of beta-blockers.   
The study primary end point was a composite 
score of weighted values combining death from 
any cause, a first hospitalization for heart failure, 
and change in the quality of life.  Individual 
scores could range from +2 (positive outcome) to 




There were 518 patients that received 
isosorbide dinitrate combined with hydralazine 
compared with 532 placebo recipients.  The 
primary composite score was -0.1 +1.9 in the 
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treatment group compared with -0.5 +2.0 in the 
placebo group (P=0.01)  Individual endpoints 
were 43% reduction in the rate of death from any 
cause (hazard ratio, 0.57, P = 0.01), 33% relative 
reduction in the rate of first hospitalization for 
heart failure (16.4% vs. 22.4%, P= 0.001), and 
improvement in the quality of life (change in 
score, -5.6 +20.6 vs. -2.7 +21.2, with lower scores 
indicating better quality of life, P= 0.02, range of 
possible values, 0 to 105). 
The trial was stopped after a ten month mean 
duration of follow-up when survival analysis 
revealed a significantly higher mortality rate in 
the placebo group than in the treatment group 
(10.2% vs. 6.2%, P=0.02). 
 
Author Conclusions 
Isosorbide dinitrate plus hydralazine in a fixed 
dosage combined with existing standard heart 
failure therapy was beneficial and increased 
survival in black heart failure patients.   
 
Commentary 
The mortality benefit of combined isosorbide 
dinitrate with hydralazine was described in an 
earlier study of Veterans Administration male 
patients already receiving digoxin and diuretics 
(Vasodilator-Heart Failure Trial (V-HeFT I).  This 
randomized, placebo-controlled, double-blind 
study identified a 36% mortality-risk reduction by 
three years in the trial group treated with 
isosorbide plus hydralazine (I-H), compared with 
a prazosin-treatment group, and a placebo-
treatment group.  The majority of patients in this 
trial were non-African American; however the 
greatest benefit was shown in the African 
American I-H-treated group.5 
Studies of vasodilatory drug effects in African 
Americans have shown a reduced response to 
nitric oxide-mediated therapies.6,7  Isosorbide 
dinitrate stimulates the nitric oxide pathway and 
hydralazine has antioxidant properties that inhibit 
superoxide synthesis.  The combined effects of 
these two agents may help restore the balance of 
nitric oxide and superoxide synthesis in African 
Americans by dilating both arteries and veins.8 
Other antihypertensive agents have been 
identified as less effective in blacks.  Beta-
blockers and ACEIs, when administered as 
monotherapy, were less effective in blood 
pressure-lowering efficacy for black as compared 
with white patients.3  Enalapril (Vasotec) is an 
example of an ACEI found to have less 
antihypertensive effect in black patients than in 
non-blacks.9  In addition, it should be noted that 
black patients receiving ACEIs have been 
reported to have a higher incidence of angioedema 
compared to non-blacks.  The African-American 
Study of Kidney Disease and Hypertension Study 
Group identified the CCB, amlodipine (Norvasc), 
as less renoprotective compared with the ACEI, 
ramipril (Altace), in blacks with hypertensive 
renal insufficiency.10  The antihypertensive effect 
of the ARB, losartan (Cozaar), is somewhat less 
in black patients.11  
Despite these differences, all antihypertensive 
drug classes are associated with blood pressure 
lowering efficacy and improved outcomes in 
blacks as well as non-blacks.3 
A new drug application has been filed with the 
FDA by NitroMed Inc. for a combination product 
containing isosorbide dinitrate and hydralazine.  
The product BiDil will be a fixed-dose oral 
combination.  It will be indicated for the treatment 
of heart failure in African Americans.  Product 
launch is expected in 2005.12 
As demonstrated in this study by Taylor et al 
the addition of isosorbide dinitrate plus 
hydralazine as a fixed-dose combination with 
standard heart failure therapy is efficacious and 
increases survival in black patients [Evidence 
level A; high-quality RCT].4 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based 
clinical review article.  Am Fam Physician 2002;65:251-8. 
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